{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:43:20Z","timestamp":1760233400872,"version":"build-2065373602"},"reference-count":66,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In this review, we briefly outline our current knowledge on the epidemiology, outcomes, and pathophysiology of heart failure (HF) with mid-range ejection fraction (HFmrEF), and discuss in more depth the evidence on current treatment options for this group of patients. In most studies, the clinical background of patients with HFmrEF is intermediate between that of patients with HF and reduced ejection fraction (HFrEF) and patients with HF and preserved ejection fraction (HFpEF) in terms of demographics and comorbid conditions. However, the current evidence, stemming from observational studies and post hoc analyses of randomized controlled trials, suggests that patients with HFmrEF benefit from medications that target the neurohormonal axes, a pathophysiological behavior that resembles that of HFrEF. Use of \u03b2-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and sacubitril\/valsartan is reasonable in patients with HFmrEF, whereas evidence is currently scarce for other therapies. In clinical practice, patients with HFmrEF are treated more like HFrEF patients, potentially because of history of systolic dysfunction that has partially recovered. Assessment of left ventricular systolic function with contemporary noninvasive modalities, e.g., echocardiographic strain imaging, is promising for the selection of patients with HFmrEF who will benefit from neurohormonal antagonists and other HFrEF-targeted therapies.<\/jats:p>","DOI":"10.3390\/jcm10020203","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T19:55:56Z","timestamp":1610308556000},"page":"203","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Heart Failure with Mid-Range Ejection Fraction: What Is the Evidence"],"prefix":"10.3390","volume":"10","author":[{"given":"Eleni-Evangelia","family":"Koufou","sequence":"first","affiliation":[{"name":"Division of Cardiology, University of Patras, 26504 Rio, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelos","family":"Arfaras-Melainis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-0725","authenticated-orcid":false,"given":"Sahil","family":"Rawal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook Renaissance School of Medicine, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-429X","authenticated-orcid":false,"given":"Andreas P.","family":"Kalogeropoulos","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Stony Brook Renaissance School of Medicine, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/ejhf.159","article-title":"The middle child in heart failure: Heart failure with mid-range ejection fraction (40\u201350%)","volume":"16","author":"Lam","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jchf.2017.06.013","article-title":"Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions","volume":"5","author":"Hsu","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-019-00451-0","article-title":"Heart Failure With Mid-range Ejection Fraction","volume":"17","author":"Srivastava","year":"2020","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.798","article-title":"Heart failure with mid-range ejection fraction: A distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)","volume":"19","author":"Rickenbacher","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","article-title":"Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/ejhf.1091","article-title":"Predictors and outcomes of heart failure with mid-range ejection fraction","volume":"20","author":"Bhambhani","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2459\/JCM.0000000000000653","article-title":"Characteristics and outcome for heart failure patients with mid-range ejection fraction","volume":"19","author":"Wang","year":"2018","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/ehf2.12353","article-title":"The prognosis of mid-range ejection fraction heart failure: A systematic review and meta-analysis","volume":"5","author":"Altaie","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/ejhf.879","article-title":"Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction","volume":"19","author":"Rastogi","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11936-018-0628-9","article-title":"Heart Failure with Recovered EF and Heart Failure with Mid-Range EF: Current Recommendations and Controversies","volume":"20","author":"Unkovic","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","article-title":"Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction","volume":"296","author":"Vergaro","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ehjci\/jez014","article-title":"Value of combined cardiopulmonary and echocardiography stress test to characterize the haemodynamic and metabolic responses of patients with heart failure and mid-range ejection fraction","volume":"20","author":"Pugliese","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jchf.2017.04.007","article-title":"Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction","volume":"5","author":"Tromp","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ejhf.911","article-title":"The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction","volume":"19","author":"Gohar","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamacardio.2016.1325","article-title":"Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction","volume":"1","author":"Kalogeropoulos","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: Moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ejhf.807","article-title":"Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study","volume":"19","author":"Tsuji","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/2048872619827476","article-title":"Beta-blockers for post-acute coronary syndrome mid-range ejection fraction: A nationwide retrospective study","volume":"8","author":"Carvalho","year":"2019","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.15420\/cfr.2018:10:1","article-title":"Heart Failure with Mid-Range Ejection Fraction and How to Treat It","volume":"4","author":"Lopatin","year":"2018","journal-title":"Card Fail. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: Characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/03007995.2018.1520695","article-title":"Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction","volume":"35","author":"Xin","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e14967","DOI":"10.1097\/MD.0000000000014967","article-title":"Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials","volume":"98","author":"Xiang","year":"2019","journal-title":"Medicine"},{"key":"ref_30","first-page":"339","article-title":"Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction","volume":"7","author":"Enzan","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Nie, D., Xiong, B., Qian, J., Rong, S., Yao, Y., and Huang, J. (2020). The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis. Heart Lung Circ.","DOI":"10.1016\/j.hlc.2020.10.012"},{"key":"ref_33","first-page":"68","article-title":"The impact of heart rate on patients diagnosed with heart failure with mid-range ejection fraction","volume":"21","author":"Xin","year":"2019","journal-title":"Anatol. J. Cardiol."},{"key":"ref_34","first-page":"A10199","article-title":"Atrial fibrillation is associated with impaired exercise capacity and adverse prognosis in patients with heart failure with mid-range ejection fraction","volume":"140","author":"Sato","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"iv6","DOI":"10.1136\/hrt.2005.078790","article-title":"Inhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazine","volume":"92","author":"Belardinelli","year":"2006","journal-title":"Heart"},{"key":"ref_38","first-page":"66","article-title":"Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure","volume":"9","author":"Murray","year":"2014","journal-title":"Heart Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/ejhf.1160","article-title":"Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction","volume":"20","author":"Shen","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/1479164118794619","article-title":"Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function","volume":"15","author":"Johansson","year":"2018","journal-title":"Diab. Vasc. Dis. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1016\/j.amjmed.2020.04.006","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials","volume":"133","author":"Kumar","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Cui, D., Liao, Y., Li, G., and Chen, Y. (2020). Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials. Am. J. Cardiovasc. Drugs, 1\u20139.","DOI":"10.1007\/s40256-020-00416-y"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jchf.2017.05.001","article-title":"Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction","volume":"5","author":"Sartipy","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1093\/eurheartj\/ehy626","article-title":"Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: A report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry","volume":"39","author":"Zafrir","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/00015385.2019.1610834","article-title":"Association between atrial fibrillation and heart failure with different ejection fraction categories and its influence on outcomes","volume":"75","author":"Xu","year":"2020","journal-title":"Acta Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00392-016-1063-0","article-title":"Acute heart failure with mid-range left ventricular ejection fraction: Clinical profile, in-hospital management, and short-term outcome","volume":"106","author":"Farmakis","year":"2017","journal-title":"Clin. Res. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1253\/circj.CJ-18-0543","article-title":"Comparison of Characteristics and 3-Year Outcomes in Patients With Acute Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction","volume":"83","author":"Cho","year":"2019","journal-title":"Circ. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1536\/ihj.19-211","article-title":"Recovered Left Ventricular Ejection Fraction and Its Prognostic Impacts in Hospitalized Heart Failure Patients with Reduced Ejection Fraction","volume":"61","author":"Abe","year":"2020","journal-title":"Int. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry","volume":"7","author":"Linssen","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: A systematic review of randomized clinical trials","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ehf2.12455","article-title":"Heart failure with mid-range ejection fraction: Characterization of patients from the PINNACLE Registry(R)","volume":"6","author":"Ibrahim","year":"2019","journal-title":"ESC Heart Fail."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1536\/ihj.18-671","article-title":"A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure","volume":"60","author":"Kinugawa","year":"2019","journal-title":"Int. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.amjcard.2015.12.060","article-title":"Impact of Physical Inactivity on Mortality in Patients With Heart Failure","volume":"117","author":"Doukky","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10741-017-9624-5","article-title":"Left ventricular ejection fraction as therapeutic target: Is it the ideal marker?","volume":"22","author":"Katsi","year":"2017","journal-title":"Heart Fail. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2007.02.055","article-title":"A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: The benefit depends on the type of training performed","volume":"49","author":"Haykowsky","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1745-6215-12-92","article-title":"A meta-analysis of the effects of exercise training on left ventricular remodeling following myocardial infarction: Start early and go longer for greatest exercise benefits on remodeling","volume":"12","author":"Haykowsky","year":"2011","journal-title":"Trials"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jacc.2013.09.052","article-title":"Impaired systolic function by strain imaging in heart failure with preserved ejection fraction","volume":"63","author":"Shah","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ehf2.12159","article-title":"Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: Outcomes following an acute heart failure hospitalization","volume":"4","author":"Buggey","year":"2017","journal-title":"ESC Heart Fail."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.echo.2019.06.017","article-title":"Myocardial Strain for Identification of beta-Blocker Responders in Heart Failure with Preserved Ejection Fraction","volume":"32","author":"Park","year":"2019","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e015009","DOI":"10.1161\/JAHA.119.015009","article-title":"Phenotyping Heart Failure According to the Longitudinal Ejection Fraction Change: Myocardial Strain, Predictors, and Outcomes","volume":"9","author":"Park","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cardfail.2011.10.019","article-title":"Echocardiographic evaluation of left ventricular structure and function: New modalities and potential applications in clinical trials","volume":"18","author":"Kalogeropoulos","year":"2012","journal-title":"J. Card. Fail."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2016.12.012","article-title":"A Test in Context: Myocardial Strain Measured by Speckle-Tracking Echocardiography","volume":"69","author":"Collier","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jacc.2004.05.068","article-title":"Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiography: A comparison with magnetic resonance imaging","volume":"44","author":"Malm","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ejhf.1621","article-title":"Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis","volume":"22","author":"Segar","year":"2020","journal-title":"Eur. J. Heart Fail."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/2\/203\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:08:23Z","timestamp":1760159303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/2\/203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["jcm10020203"],"URL":"https:\/\/doi.org\/10.3390\/jcm10020203","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2021,1,8]]}}}